Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.64 |
| ▸ | ACE | P12821 | 6/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987963 | 1.00 | FAAH (0.64) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL11793269 | 1.00 | FAAH (0.64) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL15692406 | 0.94 | PSMB5 (0.66) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL7893850 | 0.92 | MME (0.63) | FAAHACEITGB3ITGA2BMME | |
| SCHEMBL2565532 | 0.91 | FAAH (0.73) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL15155391 | 0.91 | FAAH (0.73) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL9716668 | 0.91 | FAAH (0.73) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL9666252 | 0.89 | FAAH (0.79) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL8467930 | 0.89 | FAAH (0.79) | FAAHACEPSMB5ITGB3ITGA2B | |
| SCHEMBL16449189 | 0.89 | PSMB5 (0.60) | FAAHACEPSMB5CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | claimed |
| EP-3977112-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | Metabolon Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2020242744-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| US-4859653-A | Use of compositions of matter containing N-acylates of alpha aminoacids for the treatment of skin | MORELLE JEAN V (FR) | 1989-08-22 | — | — | US | claimed |
| EP-3805237-B1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | JIANGSU CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4387638-A1 | GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN AND USE AS A LIVE DELIVERY AND PRODUCTION SYSTEM | BiomEdit, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
| US-4442090-A | ACYLATED AMINO ACID | KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1984-04-10 | — | — | US | disclosed |
| US-4151198-A | Resolution of N-acyl-DL (+)-phenylalanines | AMERICAN CYANAMID COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | FAAH 2753/4885ACE 166/4885PSMB5 3698/4885 |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | FAAH 858/4885ACE 684/4885PSMB5 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.